Latest news with #NasdaqHelsinki
Yahoo
4 days ago
- Business
- Yahoo
Vaisala Corporation: Managers' Transactions – Lindfors, Heli
Vaisala CorporationManagers' TransactionsJune 6, 2025, at 09:00 a.m. (EEST) Vaisala Corporation: Managers' Transactions – Lindfors, Heli ____________________________________________ Person subject to the notification requirementName: Lindfors, HeliPosition: Chief Financial OfficerIssuer: Vaisala OyjLEI: 743700RNDD7KU11HW873 Notification type: INITIAL NOTIFICATIONReference number: 743700RNDD7KU11HW873_20250605161406_75____________________________________________ Transaction date: 2025-06-05Venue not applicableInstrument type: SHAREISIN: FI0009900682Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 750 Unit price: 0.00 EUR Aggregated transactions(1): Volume: 750 Volume weighted average price: 0.00 EURMore information:Niina Ala-Luopa+358 400 728 957, ir@ Distribution:Nasdaq HelsinkiKey Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange. in to access your portfolio
Yahoo
4 days ago
- Business
- Yahoo
Vaisala Corporation's conveyance of treasury shares in accordance with share-based incentive plan
Vaisala CorporationStock exchange releaseJune 5, 2025, at 5:30 p.m. (EEST) Vaisala Corporation's conveyance of treasury shares in accordance with share-based incentive plan A total of 750 of Vaisala Corporation's treasury shares have been conveyed without consideration to a person participating in the Restricted Share Unit Plan 2022–2026 under the terms and conditions of the plan. The directed share issue was based on an authorization given by the Annual General Meeting held on March 25, 2025. Following this directed share issue, the number of series A treasury shares is 118, informationNiina Ala-Luopa+358 400 728 957, ir@ DistributionNasdaq HelsinkiKey Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange. in to access your portfolio
Yahoo
30-05-2025
- Business
- Yahoo
eQ Plc Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10
eQ Plc Stock Exchange Release30 May 2025, at 11.00 Plc has on 29 May 2025, received a notification under Chapter 9, Section 5 of the Finnish Securities Market Act, according to which Rettig Oy Ab's holding in eQ Plc's shares and votes has fallen below 15.00 percent. The change in ownership is due to Rettig Oy Ab's sale of shares on 28 May 2025 to eQ Plc's CEO elect, Jouko Pölönen, as announced on 5 May 2025. On 28 May 2025, Rettig Oy Ab's holding fell to 14.55 percent of eQ Plc's shares and votes. Total positions of person(s) subject to the notification obligation: % of shares and voting rights (A) % of shares and voting rights through financial instruments (B) Total of both in % (A+B) Total number of shares and voting rights of issuer Resulting situation on the date on which threshold was crossed or reached 14.55% 14.55% 41 407 198 Position of previous notification 15.53% 15.53% Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: shares and voting rights Class/type of shares ISIN code Number of shares and voting rights % of shares and voting rights Direct(SMA 9:5) Indirect(SMA 9:6 and 9:7) Direct(SMA 9:5) Indirect(SMA 9:6 and 9:7) FI0009009617 6 024 866 (Rettig Oy Ab) 6 024 866 (Rettig Capital Oy Ab) 14.55% (Rettig Oy Ab) 14.55% (Rettig Capital Oy Ab) SUBTOTAL A 6 024 866 14.55 % Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both Rettig Capital Oy Ab 00 Rettig Oy Ab 14.55%6 024 866 eQ Plc Additional information: Juha Surve, Group General Counsel, tel. +358 9 6817 8733 Distribution: Nasdaq Helsinki, media eQ is a Finnish group of companies specialising in asset management and corporate finance business. eQ Asset Management offers a wide range of asset management services (including private equity funds and real estate asset management) for institutions and individuals. The assets managed by the group total approximately EUR 13.6 billion. Advium Corporate Finance, which is part of the group, offers services related to mergers and acquisitions, real estate transactions and equity capital markets. The share of the group's parent company eQ Plc is listed on Nasdaq Helsinki. More information about the group is available on our website at while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Vaisala Corporation: Managers' Transactions – Voipio, Raimo
Vaisala CorporationManagers' TransactionsMay 28, 2025, at 5:00 p.m. (EEST) Vaisala Corporation: Managers' Transactions – Voipio, Raimo ____________________________________________ Person subject to the notification requirementName: Raimo VoipioPosition: Member of the Board/Deputy memberIssuer: Vaisala OyjLEI: 743700RNDD7KU11HW873 Notification type: INITIAL NOTIFICATIONReference number: 110180/5/4 ____________________________________________ Transaction date: 2025-05-28Outside a trading venueInstrument type: SHAREISIN: FI0009900682Nature of transaction: GIFT,DONATION OR INHERITANCE (MADE) Transaction details(1): Volume: 95 Unit price: 50 EUR (2): Volume: 95 Unit price: 50 EUR Aggregated transactions (2): Volume: 190 Volume weighted average price: 50 EURMore information:Niina Ala-Luopa+358 400 728 957, ir@ Distribution:Nasdaq HelsinkiKey Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange.
Yahoo
23-05-2025
- Business
- Yahoo
Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market
ORION CORPORATION PRESS RELEASE 23 MAY 2025 at 12.40 EEST Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited ('Shilpa'), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa's Recombinant Human Albumin is developed using a robust non-human expression system ensuring high safety, scalability, and virus-free production, addressing key limitations associated with human-derived albumin. The product is currently under development by Shilpa. Under the terms of the agreement, Orion will gain exclusive right to distribute, market and sell Shilpa's Recombinant Human Albumin in Europe. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments. 'We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product,' said Satu Ahomäki, EVP Generics and Consumer Health, Orion Corporation. 'Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe.' 'Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental and manufacturing capabilities to bring Recombinant Human Albumin to market,' said Madhav Bhutada, Managing Director, Shilpa Biocare. 'This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets.' Orion Corporation Contact person:Satu Ahomäki, EVP, Generics and Consumer Health, Orion Corporation tel. +358 10 426 7616 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp:// Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.
